AffaMed Therapeutics (AffaMed), a global clinical-stage biopharmaceutical company, announced that Dextenza has been approved in Macau, China for the treatment of ocular inflammation and pain following ophthalmic surgery.
In 2020, AffaMed Therapeutics entered into a licensing agreement with Ocular Therapeutix for the development and commercialization of Dextenza in Greater China, South Korea, and certain ASEAN markets. Dextenza is currently approved in the US for the treatment of ocular inflammation and pain following ophthalmic surgery and for the treatment of ocular itching associated with allergic conjunctivitis.
Dr. Dayao Zhao, CEO of AffaMed commented: "We are encouraged by the Macau government
